Risks and who should avoid it Because GLP-1 microdosing exists entirely outside of FDA-approved guidelines, there is currently no clinical trial data establishing its safety or efficacy
Purpose-built for physicians Study: Semaglutide slowed progression of CKD, cut cardiovascular events, mortality risk Key takeaways: FLOW trial results showed a 24% lower risk of kidney disease events and an 18% lower risk of cardiovascular events
With insurance, semaglutide's cost is often reduced significantly
Analysis of clinical chemistry parameters measured at the end of the 4-week study (Supplementary Table 11) showed that MEDI4166 treatment reduced FPG, total cholesterol and serum alanine transaminase (ALT) levels, which is indicative of improved liver function
Begin by reviewing your medical history and ensuring your healthcare provider is fully aware of all medications, supplements, and health conditions you have
This slowed metabolism can make you feel more tired